GlaxoSmithKline requests emergency authorization from FDA for Covid antibody drug

Business

In this article

In this photo illustration the British multinational pharmaceutical company GlaxoSmithKline (GSK) logo seen displayed on a smartphone with a computer model of the COVID-19 coronavirus on the background.
Budrul Chukrut | SOPA Images | Getty Images

GlaxoSmithKline and Vir Biotechnology on Friday applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.

The FDA submission is based on an interim analysis of a phase three trial, which evaluated the drug for the early treatment of Covid-19 in adults at high risk of hospitalization. The drug reduced hospitalizations or death from Covid-19 by 85% compared with a placebo.

The two companies in August started testing the antibody on early-stage Covid-19 patients, hoping to keep symptoms from progressing.

This is a developing story. Please check back for updates.

-Reuters contributed to this report.

Articles You May Like

74% of consumers are concerned about a recession: 5 steps you can take now to prepare
‘Minions: The Rise of Gru’ tops $108 million as parents flock back to cinemas, kids in tow
British Army’s Twitter and YouTube accounts hacked to promote cryptocurrency scams
Settled medical debt is now dropping off credit reports — here’s how to check your record and make sure it’s right
This former financial advisor pivoted to teach advisors about crypto: ‘A lot of folks are convinced it’s a fad or it’s a fraud’